INTRODUCTION

Cholestasis occurs from obstruction of bile product in the biliary tract due to obstruction of the intrahepatic and extrahepatic hepatobiliary tract. The continuum of cholestasis is liver injury and structurally abnormal liver architecture defined by hepatic fibrosis and ending in cirrhosis. The other causes of liver injury and hepatic fibrosis are viral infection, metabolic, ethanol abused and malignancy. American’s Society of Liver disease accounts for approximately 15% of causes of liver failure is cholestasis. Europe Association of Liver Cirrhosis confirmed 20% of hepatic fibrosis is due to abnormality of the biliary tract that induced cholestasis. There is no available data that shows the percentage of hepatic fibrosis generated by cholestasis in Indonesia. Numerous cholestasis causes include infection, bile duct stone, congenital and acquired anatomical abnormalities, and malignancy.

Sometimes, patients come to the doctor in late cholestasis conditions. Therefore, in that condition, liver injury and focal or extended hepatic fibrosis should be suspected. It is a dilemma for the clinician to treat this condition. Management of hepatic fibrosis induced by cholestasis should be as soon as possible, consists of surgical drainage or medicamentosa. Currently, there were several medications available for hepatic fibrosis, such as Ursodeoxycholic acid (UDCA), Curcumin, Vitamins (C and E) and antioxidants agents, to assist hepatocyte healing. However, those drugs work in unknown mechanisms in reducing the injury and hepatic fibrosis induced by cholestasis.

Glutathione (GSH) is a protein that consists of three primary amino acids such as L-Glutamic Acid, L-Cysteine, and L-Glycine. GSH is the main thiol in cells act as a cofactor in several antioxidants and detoxifying enzymes. GSH is the mother of antioxidants in mammals. The liver produces a significant amount of GSH and excretes it into plasma and bile. Cholestasis is reducing the availability of GSH in mice blood. This condition is reducing the ability of the antioxidant system in mice. In one experimental study, GSH treatment 300 mg/kg oral for 7 days reduced total bilirubin, ALT, AST, and proinflammatory cytokine levels in the systemic circulation. GSH also impaired the activity of free radicals Nitrotyrosine (NT), Nitric Oxide (NO) and Malondialdehyde (MDA). GSH increase responsivity of endothelium that impair the activity of hepatic stellate cell and prevent hepatic fibrosis. GSH impairs Tumor Necrotizing Factor-α (TNF- α) and Interleukin-1β (IL-1 β), the proinflammatory cytokines that promote the hepatic fibrosis process. Curcumin is an active polyphenol
extracted from Curcuma xanthorriza rhizome. Curcumin has known as an antioxidant, anti-inflammatory and anti-tumor in chronic hepatic disease and malignancy. The proinflammatory cytokines increase in cholestasis. These cytokines induce Janus Kinase 2 (JAK-2) and activate the inflammatory cascade in which increases Reactive Oxygen Species (ROS), Hypoxia Inducible Factor (HIF-1) and Transforming Growth Factor (TGF 1β). All of these cytokines promote hepatic fibrosis. Curcumin impairs the proinflammatory cytokines. Therefore, it was used as an agent therapeutic of hepatic fibrosis induced by cholestasis.

The diagnosis of injury and hepatic fibrosis is performed by invasive and non-invasive examinations. Imaging examinations such as Magnetic Resonance Elastography (MRE) is a non-invasive technique, expensive, and limited. Ultrasonography with Transient elastography also has a limitation in access. Laboratory examinations such as Aminotransferee to platelet ratio index (APRI) or Fibrosis-4 (FIB-4) are standard tests despite a low accuracy level. A laboratory examination using index or scoring such as Forns Index, Fibro Index, and the BMI, Age, ALT, and Triglyceride (BAAT) score also does not reveal good accuracy. A gold standard examination of hepatic fibrosis is histopathological evaluation. It shows the appearance of liver injury characterized by the accumulation of inflammatory cells, steatosis, necrotic combined with fibrotic and collagen confined to a sophisticated finding of hepatic fibrosis. Therefore, this study aims to determine the effectiveness of two kinds of drugs, Glutathione and Curcumin, in hepatic fibrosis induced by cholestasis in Wistar rats.

**METHODS**

The experimental animals used in this study were adult (2-3 months) male Wistar rats (weighing 200-250 gram). These rats were appropriate for this research because the pathophysiology of disease and anatomy of intraperitoneal organs tend to be similar to humans based on the previous study. The rat's choledochal duct remains an inappropriate size that is helpful to identify in surgical procedure and reduce the bias and failure occur.

All rats were divided into three groups of 5 rats each. The number of samples determined with the Federer formula in which the total sample is 15 rats. Eligible samples that met inclusion criteria performed a laparotomy surgical with double ligation with 3.0 non-absorbable thread (Silk) and resection of choledochal duct (Common Bile Duct/CBD). After that, all samples were prepared with no intervention at all in 3 weeks. After 3 weeks, each group-administered different intervention. The first group as control was not performed anything at all. The second group was administered with 3.9 mg/kg oral Glutathione each day for 2 weeks. The third group was administered with 1.3 mg/kg oral Curcumin each day for 2 weeks.

Two weeks later, all rats of three groups performed a termination. After that, the liver organ of all experimental animals was obtained by resection. The resected liver has enrolled a fixation in formalin buffer 10% following histopathological examination using Hematoxylin Eosin (HE). This staining aims to determine the process of liver injury and the extension of hepatic fibrosis from each sample of the group. This follows with statistical analysis to evaluate the effectiveness of GSH and Curcumin in liver injury and hepatic fibrosis.

Data obtained were analyzed with Shapiro-Wilk for the normality test. In addition, a non-parametric statistical analysis Kruskal-Wallis was performed to test the value of the mean difference in the three groups tested. The p-value below 0.05 was considered statistically significant. Data were analyzed using SPSS version 17 for Windows.

**RESULTS**

Regarding Kruskal-Wallis analysis, it was obtained a mean value that statistically significant in evaluating fibrous tissue/collagen with A scoring system and cytology with B scoring system in each treated group (p<0.05) (Table 1). Glutathione treated group revealed the lowest mean value (0.66±0.34) compared to the curcumin-treated group (1.06±0.37) and control (2.46±0.38) using A scoring system (Table 1). On the other hand, using the B scoring system obtained the lowest mean value in the glutathione treated group (1.53±0.30) compared to the curcumin-treated group (2.33±0.33) and control (4.00±0.00). The analysis between the control group and both glutathione and curcumin-treated group showed statistically significant differences (p<0.05). The analysis between the glutathione treated and curcumin-treated groups using the A or B scoring system showed differences, but it was not statistically significant (p>0.05) (Table 1).

**DISCUSSION**

Cholestasis increased the availability of free radicals (Nitrosamine, Nitric Oxide, and Malondyaldehyde) and pro-inflammatory cytokines (Tumor Necrotizing Factor and Interleukin 1-β). Free radicals and pro-inflammatory cytokines induced Hepatic Stellate Cell (HSC) and recruited Extracellular Matrix (ECM). Inflammatory cell accumulation, steatosis and necrotic liver cells were a continuum process to liver injury. The livers' regenerating system would repair this injury; unless it was failed, this process ended with hepatic fibrosis. In this study, all experimental rats have performed a
CBD double ligation with 3.0 Silk and resection to prevent the CBD regeneration process. Therefore, the CBD was occluded and induced cholestasis process.

Regarding previous study findings, cholestasis induced by ligation of CBD for more than 3 weeks in mice was enough to cause hepatic fibrosis. This condition occurred due to the accumulation of bile products and bile acid-induced biliary cells activating inflammatory mediators such as TNF-α, Endothelin-1, PDGF and others. In addition, they promoted HSC and recruited ECM and collagen. Those complex process was related to pro-inflammatory factors and free radical agents. A liver injury process that was not appropriately treated would be ended with fibrosis and cirrhosis. The management of cholestasis was surgical biliary drainage. It would prevent the following injury and fibrosis.

On the other hand, sometimes the drainage could not continually be enrolled to people who suffered cholestasis. It might be due to the patient's condition, lack of medical utility and lack of medical staff's competency. It was also not an easy decision to perform a surgical way nowadays, due to pandemic Covid 19. Therefore, to prevent the neglected case of cholestasis, we should consider the other significant interventions to do as soon as possible and avoid fibrosis and cirrhosis.

GSH and Curcumin were drugs acting as antioxidants, disrupting free radicals and pro-inflammatory factors to work and preventing liver injury and hepatic fibrosis. Despite their antioxidant effect, literature informed that both of them had a different mechanism of action. This condition, we would compare their effectiveness and other effects in liver injury and hepatic fibrosis. GSH was a mother of antioxidants and usually produced by the liver in specific amounts as a free radical controller. In mammals, these natural antioxidants would be decreasing, in concordance with impairing of biliary cells. Thus, we should add external antioxidants to enhance their protecting activity in liver cells. Curcumin was an active polyphenol. It had antioxidants and mild anti-inflammation. Curcumin was not produced endogenously. It acted through the kinase pathway and prevented the continuum of liver injury and hepatic fibrosis. GSH and Curcumin were given for 2 weeks based on daily dose. The other studies recommended GSH and Curcumin were given for 10-14 days to reach the maximal effect. Eshaghian A et al. Recommended Curcumin with a dose of 100 mg/kg each day for 10 days.

This study revealed that liver injury and hepatic fibrosis were reduced significantly. This was proper to previous literature and studies. Thus, this study could be another reference of non-surgical interventions in liver injury and hepatic fibrosis-induced cholestasis. GSH and Curcumin should be considered to give before the surgery was performed. Based on statistical analysis findings, the effect of GSH and Curcumin to reduce liver injury and hepatic fibrosis did not differ significantly. Still, the GSH score is better than Curcumin one. This study showed that, even though the mechanism of action GSH and Curcumin differ, their effect was fair but better than the control group. It may happen due to their similar activity in decreasing the inflammatory process and free radicals involved in hepatic fibrosis.

The histopathology examination using HE staining of three groups showed a sophisticated liver injury process and hepatic fibrosis induced by cholestasis. The accumulation of bile promotes inflammation of biliary cells and induces inflammatory cells, steatosis and necrotizing cells. The hallmark of hepatic fibrosis in histopathology examination was the accumulation of fibrous tissue/collagen at all specimens in different quantities and collagen in the liver. Therefore, in the conceptual framework, data gathering, data analysis until reporting the study results through publication.

CONCLUSION

Regarding the results of this study, GSH and Curcumin were effective and statistically significant in reducing the injury process and hepatic fibrosis induced by cholestasis. However, despite their effectiveness, the differential effect between GSH and Curcumin was not statistically significant.

CONFLICT OF INTEREST

There is no competing interest regarding the manuscript.

ETHICS CONSIDERATION

Ethics approval has been obtained from the Ethics Committee, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia, prior to the study being conducted.

FUNDING

None.

AUTHORS CONTRIBUTION

All authors equally contribute to the study from the conceptual framework.


